It is known that the vast majority of experience and regulatory history of using cell culture to produce vaccines is with mammalian cell-lines, but is it time for change?
- Is it economically viable to stop using mammalian cell lines for vaccine production or are re-investment figures too substantial?
- From a purely scientific perspective, can non-mammalian cell lines deliver a wide enough range of vaccines to justify their exclusive use?
- Will the draw of faster production cycles and cheaper process developments out-weigh all other concerns?
Dr Shyam Subramanian the Vaccine Expression Systems Lead at Merck Sharp & Dohme is exploring the potential of whether complex vaccines can be achieved without mammalian cell lines at the World Vaccine Cell Culture Congress in Washington D.C. in Spring 2012.
- Are mammalian cells the only option for manufacturing complex vaccines?
- When should one look for alternatives, and what strategy should be used to screen alternative non-mammalian cell substrates for vaccine production?
- What are the current limitations of alternative non-mammalian cell substrates , and how can they be overcome ?
REGISTER TODAY to secure your place at the forum for cell culture vaccine production and I look forward to welcoming you in the Spring